Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SPRO
SPRO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SPRO News
Kailera Appoints New Chief Corporate Affairs Officer
6d ago
Globenewswire
Biotech Sector Sees FDA Approvals and Layoffs
Jun 19 2026
NASDAQ.COM
GSK and Spero Gain FDA Approval for New Antibiotic
Jun 18 2026
NASDAQ.COM
First Oral Carbapenem Antibiotic Approved in the US
Jun 17 2026
Newsfilter
First Oral Carbapenem Antibiotic Approved in the US
Jun 17 2026
Newsfilter
GSK and Spero's Utebzi Approved by FDA for UTIs
Jun 17 2026
seekingalpha
Compass Pathways Appoints New Board Member
May 28 2026
Newsfilter
Spero Therapeutics Reports Fourth Quarter Revenue of $41.3 Million
Mar 26 2026
moomoo
Spero Therapeutics Reports Strong Q4 Earnings
Mar 26 2026
seekingalpha
SPERO THERAPEUTICS REPORTS Q4 NET INCOME OF $31.52 MILLION
Mar 26 2026
moomoo
Spero Therapeutics Reports Q4 Operating Income of $31.405 Million
Mar 26 2026
moomoo
Spero Therapeutics Reports Q4 Operating Expenses of $9.892 Million
Mar 26 2026
moomoo
Spero Therapeutics and GSK Submit NDA for Tebipenem HBr, Triggering $25 Million Milestone Payment
Dec 19 2025
Globenewswire
Spero Therapeutics and GSK Submit NDA for Tebipenem HBr, Triggering $25M Milestone Payment
Dec 19 2025
Newsfilter
Spero Therapeutics Grants 90,000 RSUs to New Employee Under 2019 Inducement Plan
Nov 28 2025
Globenewswire
Spero Therapeutics Grants 90,000 RSUs to New Employee Under 2019 Inducement Plan
Nov 28 2025
Newsfilter
Show More News
